Janssen Research & Development LLC, 3210 Merryfield Row, San Diego, CA, 92121, USA.
Mol Imaging Biol. 2019 Oct;21(5):871-878. doi: 10.1007/s11307-018-01313-2.
The P2X7 receptor, an adenosine triphosphate (ATP)-gated purinoreceptor, has emerged as one of the key players in neuroinflammatory processes. Therefore, developing a positron emission tomography (PET) tracer for imaging of P2X7 receptors in vivo presents a promising approach to diagnose, monitor, and study neuroinflammation in a variety of brain disorders. To fulfill the goal of developing a P2X7 PET ligand as a biomarker of neuroinflammation, [F]JNJ-64413739 has been recently disclosed.
We evaluated [F]JNJ-64413739 in a rat model of neuroinflammation induced by an intracerebral injection of lipopolysaccharide (LPS). In vivo brain uptake was determined by PET imaging. Upregulation of neuroinflammatory biomarkers was determined by quantitative polymerase chain reaction (qPCR). Distribution of the tracer in the brain was determined by ex vivo autoradiography (ARG). The specificity of [F]JNJ-64413739 was confirmed by performing blocking experiments with the P2X7 antagonist JNJ-54175446.
Brain regions of rats injected with LPS had a significantly increased uptake (34 % ± 3 % s.e.m., p = 0.036, t test, standardized uptake value measured over the entire scanning period) of [F]JNJ-64413739 relative to the corresponding brain regions of control animals injected with phosphate-buffered saline (PBS). The uptake in the contralateral regions and cerebellum was not significantly different between the groups of animals. The increase in uptake of [F]JNJ-64413739 at the LPS-injected site observed by PET imaging was concordant with ex vivo ARG, upregulation of neuroinflammatory biomarkers, and elevated P2X7 expression levels.
While further work is needed to study [F]JNJ-64413739 in other types of neuroinflammation, the current results favorably characterize [F]JNJ-64413739 as a potential PET tracer of central neuroinflammation.
P2X7 受体是一种三磷酸腺苷(ATP)门控嘌呤受体,已成为神经炎症过程中的关键参与者之一。因此,开发一种正电子发射断层扫描(PET)示踪剂来体内成像 P2X7 受体,为诊断、监测和研究各种脑疾病中的神经炎症提供了一种很有前途的方法。为了开发一种作为神经炎症生物标志物的 P2X7 PET 配体,最近披露了[F]JNJ-64413739。
我们在由脂多糖(LPS)脑内注射诱导的大鼠神经炎症模型中评估了[F]JNJ-64413739。通过 PET 成像确定脑内摄取。通过定量聚合酶链反应(qPCR)确定神经炎症生物标志物的上调。通过离体放射自显影(ARG)确定示踪剂在大脑中的分布。通过使用 P2X7 拮抗剂 JNJ-54175446 进行阻断实验,证实了[F]JNJ-64413739 的特异性。
与用磷酸盐缓冲盐水(PBS)注射的对照动物相比,LPS 注射大鼠的脑区[F]JNJ-64413739 的摄取显著增加(34%±3%标准误,p=0.036,t 检验,整个扫描期间测量的标准化摄取值)。动物组之间对侧区域和小脑的摄取没有显著差异。PET 成像观察到的 LPS 注射部位[F]JNJ-64413739 摄取的增加与离体 ARG、神经炎症生物标志物的上调以及 P2X7 表达水平的升高一致。
虽然需要进一步的工作来研究其他类型的神经炎症中的[F]JNJ-64413739,但目前的结果有利地将[F]JNJ-64413739 描述为中枢神经炎症的潜在 PET 示踪剂。